Critical tumor suppression pathways in brain tumors have yet to be fully defined. Along with mutational analyses, genome-wide epigenetic investigations may reveal novel suppressor elements. Using differential methylation hybridization, we identified a CpG-rich region of the promoter of the dual-specificity mitogenactivated protein kinase phosphatase-2 gene (DUSP4/MKP-2) that is hypermethylated in gliomas. In 83 astrocytic gliomas and 5 glioma cell lines examined, hypermethylation of the MKP-2 promoter was found to occur relatively more frequently in diffuse or anaplastic astrocytomas and secondary glioblastomas relative to primary glioblastomas. MKP-2 hypermethylation was associated with mutations in TP53 and IDH1, exclusive of EGFR amplification, and with prolonged survival of patients with primary glioblastoma. Expression analysis established that promoter hypermethylation correlated with reduced expression of MKP-2 mRNA and protein. Consistent with a regulatory role, reversing promoter hypermethylation by treating cells with 5-aza-2′-deoxycytidine increased MKP-2 mRNA levels. Furthermore, we found that glioblastoma cell growth was inhibited by overexpression of exogenous MKP-2. Our findings reveal MKP-2 as a common epigenetically silenced gene in glioma, the inactivation of which may play a significant role in glioma development.
Introduction
Glioblastomas are the most common and most malignant tumors of the brain. They may manifest at any age, with a peak incidence between 45 and 70 years (1) . Glioblastomas are highly invasive and aggressively growing tumors that respond poorly to radiation therapy and most forms of chemotherapy. The prognosis is correspondingly poor, with most patients dying within 1 year after diagnosis. Glioblastomas may develop from diffuse astrocytomas WHO grade 2 or anaplastic astrocytomas WHO grade 3 (secondary glioblastoma), but more frequently, after a short clinical history de novo without evidence of a less malignant precursor lesion (primary glioblastoma). Glioblastomas carry complex genetic and epigenetic alterations. Primary glioblastomas frequently show loss of heterozygosity (LOH) on chromosome 10q (70% of cases), EGFR amplification (36%), p16 (INK4a) deletion (31%), and PTEN mutations (25%; ref. 2) . Secondary glioblastomas as well as their lower-grade precursor lesions exhibit frequent mutations of the TP53 and IDH1 genes (2) (3) (4) . Loss of genetic material from chromosome 10q25-qter is associated with both primary and secondary glioblastomas (2) .
In genome-wide methylation analyses using restriction landmark genome scanning and CpG island microarrays as well as a multi-candidate gene approach, cancer-related genes such as MGMT, CDKN2A, CDKN2B, p14ARF, CTMP, EMP3, SLC5A8, HIC-1, PCDH-γ-A11, BEX1, BEX2, LATS1, LATS2, RUNX3, and TES were found to be methylated in gliomas (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . MGMT promoter methylation has already gained major clinical significance because it is associated with positive response to alkylating chemotherapy and increased survival in glioblastoma patients (5) .
To better understand the molecular pathology of gliomas, we applied a genome-wide methylation analysis using the differential methylation hybridization (DMH) technology and identified several novel target genes in gliomas showing altered methylation patterns (10) . One of the identified genes encodes the dual-specificity phosphatase 4 or mitogen-activated protein kinase phosphatase 2 (DUSP4/MKP-2) gene, which is a dual serine-threonine/tyrosine phosphatase that specifically dephosphorylates and inactivates mitogenactivated protein kinases (MAPK; ref. 15) .
In this study, we present data on de novo methylation and transcriptional silencing of DUSP4/MKP-2 in primary glioma tissues and glioma cell lines. Transfection of DUSP4/MKP-2 into the DUSP4/MKP-2 methylated glioblastoma cell lines U373MG and A172 elicited growth inhibitory effects, indicating that DUSP4/MKP-2 may function as a tumor suppressor in gliomas.
Materials and Methods
Tumor samples and cell lines. We investigated 83 astrocytic tumor patients [53 primary glioblastomas WHO grade 4 (pGBM), including 4 long-time survivors with an overall survival (OS) of at least 2 y; 13 secondary glioblastomas WHO grade 4 (sGBM); 9 anaplastic astrocytomas WHO grade 3 (AAIII); and 8 diffuse astrocytomas WHO grade 2 (AII); 37 female and 46 male; mean age at surgery, 56 y; range, 26-80 y]. All tumors were classified according to the WHO classification of tumors of the central nervous system (16) . Histologic assessment confirmed that all specimens consisted of at least 80% tumor cells. Extraction of DNA and RNA was carried out as described (17) . As reference tissues for the DMH and methylation analyses, three normal brain tissues were used. Glioma cell lines A172, U373MG, U87MG, T98G, and A178 were obtained from the Ludwig Institute for Cancer Research (San Diego) and the identity has been confirmed by detection of described specific mutations in the TP53, p16, and PTEN genes. This study was approved by the ethics review committee of our institution, and written informed consent was obtained from the patients.
DMH analysis. The DMH procedure was done as described (10, 18) .
Analysis of DUSP4/MKP-2 CpG island methylation. Genomic DNAs of gliomas, glioblastoma cell lines, and nonneoplastic white matter tissues were treated with sodium bisulfite using the EpiTect Bisulfite Kit (Qiagen). Primers used for PCR amplification were DUSP4 (fw-5′-taaggagtaaggagttttaggggtt-3′) and DUSP4 (rev-5′-attttcctccccctaaatttaacta-3′). The 363-bp PCR product contains 23 putative CpG methylation sites. PCR products of bisulfite-converted DNA were cloned and sequenced as described (19) . Single-clone sequences were analyzed and methylation profiles were generated with the BiQ Analyzer software (20) .
Combined bisulfite restriction analysis. DUSP4/MKP-2 bisulfite PCR products of tumor and control DNAs were digested with BstUI (NEB). The 363-bp amplicon of DUSP4/ MKP-2 contains three BstUI restriction sites, yielding fragments of 208, 57, 54, and 44 bp when methylated. The significant presence of restriction fragments is therefore scored as methylation of the investigated region.
Tissue culture of glioblastoma cell lines and treatment with 5-aza-2′-deoxycytidine. Glioma cell lines A172, U373MG, U87MG, T98G, and A178 were cultured as described (11) . To induce DNA demethylation, the cell lines U373MG, A172, and T98G were treated with 5 μmol/L 5-aza-2′-deoxycytidine (Sigma) for 3 d and DNA and total RNA were extracted for DUSP4/MKP-2 methylation and expression analyses.
DUSP4/MKP-2 mRNA expression analysis by real-time reverse transcription-PCR and immunohistochemical staining. DUSP4/MKP-2 expression was investigated by real-time reverse transcription-PCR (RT-PCR) using the ABI PRISM 5700 sequence detection system (Applied Biosystems). The transcript level of DUSP4/MKP-2 was normalized to the transcript level of ADP-ribosylation factor 1 (ARF1; GenBank accession no. M36340). To make sure that highquality RNA was used for expression analysis, only tumors with Ct values of at most 30 cycles for the control locus ARF1 were used (range, 18.53-29.73 Primer sequences were DUSP4-RT-F, 5′-tacaagtgcatcccagtgga-3′, and DUSP4-RT-R, 5′-cccgtttcttcatcatcagg-3′, resulting in a 180-bp fragment derived from both DUSP4/MKP-2 transcript variants, and ARF1-F, 5′-gaccacgatcctctacaagc-3′, and ARF1-R3, 5′-tcccacacagtgaagctgatg-3′, resulting in a 111-bp fragment. Human brain RNA samples from corpus callosum, temporal, occipital, frontal, and parietal lobe (BioChain Institute, Inc.) as well as two additional human brain RNA samples (Stratagene; BD Biosciences) were used as references.
A tissue microarray was used to analyze the protein expression of DUSP4/MKP-2 by immunohistochemical staining on 4-μm sections with a Techmate 500 immunostainer (DAKO). Anti-DUSP4/MKP-2 antibody (Abcam) was used at a dilution of 1:100. The antigen-antibody binding was visualized with the avidin-biotin complex (ABC-method, diluted 1:50; Vectastain, Vector) using 3-amino-9-ethylcarbazol as chromogen. DUSP4/MKP-2 nuclear immunostaining was evaluated using a semiquantitative scoring system and scaled 0 and 1 (0, no expression; 1, nuclear expression).
TP53 mutation analysis. TP53 was screened for mutations in exons 4-10 using single-strand conformation polymorphism analysis as reported before (21) .
IDH1 and IDH2 mutation analyses and MGMT promoter methylation analysis. Primers IDH1-sense (5′-accaaatggcaccatacgaa-3′) and IDH1-antisense (5′-acatgcaaaatcacattattgcc-3′) spanning codon 132 and IDH2-sense (5′-ccaatggaactatccggaac-3′) and IDH2-antisense (5′-tgtggccttgtactgcagag-3′) including codon 172 were used for IDH1 and IDH2 mutation analyses. PCR products were sequenced using an ABI PRISM 377 semiautomated DNA sequencer (Applied Biosystems).
MGMT promoter methylation status was determined by methylation-specific PCR as reported elsewhere (22) .
EGFR amplification analysis. Amplification of the gene encoding the epidermal growth factor receptor (EGFR) was detected by differential PCR as reported elsewhere (23) .
DUSP4/MKP-2 cloning and transfection. DUSP4/MKP-2 plasmid was provided by Prof. Dr. M. Collins (Division of Infection and Immunity, Royal Free and University College Medical School, London, United Kingdom) and subcloned into pcDNA4/myc-His expression vector (Invitrogen). U373MG and A172 cells were transfected by lipofection (FuGENE 6, Roche) and selected by adding 400 μg/mL zeocin (Invitrogen) to the growth medium after 24 h. Approximately 2 wk later, zeocin-resistant colonies were picked and screened for DUSP4/MKP-2 expression by RT-PCR. Positive clones were expanded and used for flow cytometric analyses.
Colony formation assay. For colony formation assays, cells (2 × 10 5 per well) were seeded in 12-well tissue culture plates and transfected with either DUSP4-pcDNA4/myc-His plasmid or pcDNA4/myc-His control vector (1 μg each) using FuGENE 6 transfection reagent (Fugene, Roche). Twenty-four hours after transfection, cells were collected, seeded in 10-cm dishes, and exposed to 400 μg/mL zeocin (Invitrogen) for a total of 12 d. Cells were fixed and stained in 20% methanol and crystal violet, and colonies with >50 cells were counted. Assays were carried out at least in triplicates.
Measurement of cellular proliferation and viability by flow cytometry. U373MG and A172 cells stably expressing DUSP4-pcDNA4/myc-His plasmid or pcDNA4/myc-His control vector were serum starved for 24 h and subjected to H 2 O 2 (0.7 μmol/L) for 3 h to induce oxidative stress. For flow cytometric immunophenotyping, 1 × 10 6 cells were fixed and stained using an Alexa Fluor 647-labeled phospho-(Ser10)-histone H3 antibody (Cell Signaling Technology; 1:20) and a phycoerythrin-labeled cleaved poly(ADP-ribose) polymerase (PARP; Asp214) antibody (BD Biosciences; 1:5), as well as 4′,6-diamidino-2-phenylindole (DAPI (Sigma) to stain DNA, as described (24) . Analysis was done using a three-laser LSRII analytic flow cytometer (BD Biosciences). Data were analyzed using Flowjo (Tree Star) analysis software. At least 30,000 events were recorded per experiment. Only single cells were included in the analysis. Each experiment was carried out at least in duplicates.
Statistical analysis. All statistical analyses, including t test, Fisher's exact test, and the survival analyses, were carried out with the SPSS software (version 17). Clinical and molecular parameters were correlated with survival data established for the 51 pGBM patients. OS time was defined as the time between surgery for the primary tumor and death of the patient. Patients alive at the time of their last follow-up were censored. Survival time was compared among patient subsets using log-rank tests. For multivariate analysis of survival time, we used the Cox proportional hazard model. Following a stepwise regression strategy with an inclusion/exclusion P value of 0.1, a prognostic model was selected from the variables that already had been used in the univariate analysis.
Results
Aberrant methylation within the 5′ CpG island of DUSP4/MKP-2. Using DMH analysis, we have identified a CpG island (UCSC genome browser; CpG island 28; chr8:29266203-29266920) 2.5 kb upstream of the initiator ATG of the DUSP4/MKP-2 gene (Fig. 1A) , which is hypermethylated in gliomas. To determine the frequency and extent of de novo methylation, sodium bisulfite sequencing analyses were done on 29 gliomas (8 pGBM, 8 sGBM, 9 AAIII, and 4 AII) and 3 white matter samples (NB1-NB3). Figure 1B shows representative sequencing profiles of CpG sites [8] [9] [10] [11] [12] [13] [14] [15] [16] within the amplified region in a WHO grade 3 anaplastic astrocytoma (AA143), exhibiting methylation of all CpG sites except one (CpG site 12), and a nonneoplastic brain (white matter; NB3) showing a complete lack of methylation in this region. Significant accumulation of de novo methylation at CpG island 28 was found in sGBM and low-and high-grade astrocytomas (AII and AAIII) as well as in two of the four analyzed pGBM long-term survivors (Fig. 1C) . A second CpG island (CpG 344; chr8:29205665-29209847) containing the first exon and intron of DUSP4/MKP-2 did not show significant methylation (data not shown). The overall methylation level, determined by counting methylated CpG sites in individual clones after sodium bisulfite sequencing, was 92% in sGBM, 78% in AII, 77% in AAIII, and 47% in pGBM long-term survivors. pGBM and white matter samples showed traces of sporadic methylation (3%) and were therefore scored as nonmethylated. Some tumor samples (e.g., AA134 and A140) showed a heterogeneous methylation pattern. BstUI restriction was used for combined bisulfite restriction analysis (COBRA) of DUSP4/MKP-2 in 83 glioma samples and 5 glioma cell lines and revealed a significant concordance with data obtained by sodium bisulfite sequencing (t test P < 0.001). De novo methylation of DUSP4/MKP-2 was found in 5 of 53 (9%) pGBM, including 2 of 4 (50%) tumors from long-term survivors; 10 of 13 (77%) sGBM; 5 of 9 (56%) AAIII; 6 of 8 (75%) AII; and 4 of 5 (80%) glioma cell lines, but not in three nonneoplastic white matter samples. Figure 1D shows COBRA results obtained for 33 gliomas and 3 white matter controls. Restriction fragments indicating the presence of methylated alleles were seen in all high-and low-grade astrocytomas and in sGBM, with the exception of astrocytoma A190, but in none of the white matter tissues. Of 18 pGBM samples, only one (GB875) showed restriction fragments, indicating low-level methylation of DUSP4/MKP-2. The data show that methylation of DUSP4/MKP-2 is significantly more frequent in sGBM than in pGBM (Fisher's exact test P < 0.001). This observation provides support for the concept of different genetic/epigenetic entities within this tumor group. DUSP4/MKP-2 is transcriptionally downregulated by DNA methylation. Real-time RT-PCR analyses were done to investigate if methylation directly affects mRNA expression of DUSP4/MKP-2. Reduced DUSP4/MKP-2 mRNA expression was observed in 2 of 12 (17%) pGBM, 7 of 10 (70%) sGBM, 6 of 8 (75%) AAIII, and 6 of 8 (75%) AII samples ( Fig. 2A) . There was a significant difference in DUSP4/MKP-2 mRNA transcript levels between pGBM and sGBM (t test P = 0.014). Correlation of methylation and expression data was done on 36 tumors and revealed a significant association between hypermethylation and downregulation of DUSP4/ MKP-2 transcripts in astrocytic gliomas (t test P < 0.001). Sixteen of 20 gliomas (80%) with reduced mRNA transcript levels of DUSP4/MKP-2 relative to white matter were hypermethylated, whereas only 4 of 17 (24%) gliomas without DUSP4/MKP-2 hypermethylation revealed reduced levels of DUSP4/MKP-2 transcripts. On the other hand, 10 of 12 (83%) tumors showing strong expression of DUSP4/MKP-2 mRNA were not methylated. Treatment of the glioma cell lines A172, T98G, and U373MG with 5 μmol/L 5-aza-2′-deoxycytidine resulted in 4.4-, 2.7-, and 5.5-fold increase in DUSP4/MKP-2 transcription (Fig. 2B) . Sodium bisulfite sequencing confirmed that 5-aza-2′-deoxycytidine treatment resulted in demethylation of the investigated region (see Supplementary Fig. S1 ). Our data indicate that aberrant CpG island methylation contributes to downregulation of DUSP4/MKP-2 transcription in gliomas but may not be the only cause for its inactivation because transcription is also low in a few tumor samples in the absence of DNA methylation. The majority of tumor samples with no methylation of DUSP4/MKP-2 exhibit a substantial upregulation of DUSP4/MKP-2 transcripts.
Immunohistochemical analysis of DUSP4/MKP-2 in gliomas. DUSP4/MKP-2 protein expression was analyzed using a glioma tissue microarray with representative tumor tissue samples from 49 of the 83 investigated astrocytic tumors (37 pGBM, 3 sGBM, 5 AAIII, and 4 AII). There was a significant association between hypermethylation of the DUSP4/MKP-2 promoter and reduced protein expression (P = 0.024). In detail, immunohistochemical results revealed nuclear positivity for DUSP4/MKP-2 in 13 of 37 (35%) pGBM. All of these cases lacked DUSP4/MKP-2 methylation. The majority of pGBM [24 of 37 (65%)] showed no nuclear immunoreactivity and no methylation in the promoter region of DUSP4/MKP-2, suggesting alternative modes of regulation of RNA/protein stability. None of the three sGBM, five AAIII, and four AII exhibited nuclear expression of DUSP4/MKP-2 protein.
Representative immunohistochemical data are presented in Supplementary Fig. S2 .
TP53 mutation is associated with DUSP4/MKP2 methylation. Mutation of the TP53 gene was assessed in 47 glioma samples (9 AAIII, 13 sGBM, and 25 pGBM) and was shown in 16 (34%) of the 46 tumors studied, including 4 AAIII, 8 sGBM, and 4 pGBM. TP53 mutation was significantly more frequent in tumors with DUSP4/MKP-2 methylation [9 of 15 (60%)], including 6 sGBM and 3 AAIII, than in tumors without DUSP4/MKP-2 methylation [6 of 31 (19%)], including 4 pGBM, 1 sGBM, and 1 AAIII (P = 0.028 by Fisher's exact test; Table 1 ). EGFR amplification and DUSP4/MKP2 methylation are virtually exclusive events. Amplification of the EGFR gene was investigated in 83 glioma samples (53 pGBM, 13 sGBM, 9 AAIII, and 8 AII). Copy number gain was exclusively observed in 8 of 37 (22%) pGBM samples ( Supplementary Fig. S3 ). None of the EGFR-amplified pGBM showed methylation of the DUSP4/MKP-2-associated 5′ CpG island.
Overexpression of DUSP4/MKP-2 inhibits proliferation of glioma cells. To study the influence of DUSP4/MKP-2 expression on crucial tumor biological properties such as focus formation, cellular proliferation, or apoptosis, U373MG and A172 cells were transfected with DUSP4/MKP-2. Overexpression of DUSP4/MKP-2 caused a 36% decrease in colony number in U373MG cells and a 43% decrease in A172 cells when compared with corresponding mock-transfected controls (Fig. 3A) . This association was statistically significant (P = 0.032). DUSP4/MKP-2 expression in transfected cells was monitored by RT-PCR (data not shown).
Stably transfected U373MG and A172 cells expressing DUSP4/MKP-2 or empty vector control were grown under serum-free conditions and subjected to H 2 O 2 to induce oxidative stress. This treatment has been described as a tool to measure the influence of DUSP4/MKP-2 on apoptosis in mouse embryo fibroblasts (25) . Cellular proliferation and apoptosis were measured by flow cytometric analysis using antibodies against phospho-(Ser10)-histone H3 and cleaved PARP (Asp214). The proliferation of DUSP4/MKP-2 expressing cells was reduced by 35% in U373MG cells and by 40% in A172 cells when compared with their respective controls, whereas the apoptotic cellular population was not affected (Fig. 3B) . Taken together, these findings suggest a growth inhibitory effect of DUSP4/MKP-2 on glioblastoma cells in vitro.
IDH1 mutation is associated with DUSP4/MKP-2 methylation. IDH1 mutations were found in 5 of 53 (9%) pGBM, including 3 of 4 (75%) tumors from long-term survivors; 11 of 13 (85%) sGBM; 6 of 9 (67%) AAIII; and 4 of 8 (50%) AII. All but two mutated samples showed the R132H variant; one AAIII showed the R132S and one AAIII showed the R132G variant, respectively. Two IDH2 mutation were found in 1 of 13 (8%) sGBM and 1 of 8 (13%) AII. IDH1 mutation was significantly more frequent in tumors with DUSP4/MKP-2 methylation [22 of 26 (85%)] than in tumors without DUSP4/MKP-2 methylation [3 of 56 (5%); Fisher's exact test P > 0.001].
MGMT promoter methylation status in pGBM. MGMT promoter methylation was found in 30 of 51 (59%) pGBM, including 3 of 4 (75%) long-term survivors, 3 of 5 (60%) IDH1-mutated pGBM, and one tumor without DUSP4/MKP-2 methylation.
Relationship between molecular findings and clinical data. Univariate analysis for DUSP4/MKP-2 confirmed a significantly better clinical course for patients with methylated tumors as compared to those with unmethylated tumors (OS, 1210 versus 430 days; P = 0.009), as well as for IDH1 mutations versus wild type (OS, 1,135 versus 440 days; P = 0.040) and age (separated for median, ≤63 or >63 years) at operation (OS, 653 versus 338 days; P = 0.010). In contrast, KaplanMeier survival analysis did not reveal a significant association of survival with MGMT promoter hypermethylation or preoperative Karnofsky performance status (separated for median, ≤80 or >80). Stepwise forward Cox multivariate regression analysis determined that the best model for predicting OS is age at operation (P = 0.009).
Discussion
MAPK phosphatases (MKP) are a family of dual-specificity protein phosphatases that dephosphorylate both phosphothreonine and phosphotyrosine residues in MAPKs, including (26) (27) (28) (29) (30) (31) . DUSP4/MKP-2 inactivates ERK1, ERK2, and JNK, is expressed in a variety of tissues, and is localized in the nucleus. We have identified DUSP4/ MKP-2 by a genome-wide methylation analysis as a frequent target for DNA methylation in gliomas.
The DUSP4/MKP-2 gene has two CpG islands, one spanning 1.5 kb upstream of 5′ untranslated region (UTR) to the first intron and a small island 2.5 kb upstream of 5′ UTR. We found that de novo methylation is restricted to the CpG island at 2.5 kb from the transcription start site. Methylation at this region may seed a repressive chromatin structure that diffuses to the flanking unmethylated sequence (32) . Potent silencing of transcription by DNA methylation at a distance of 2.5 kb without methylation in the promoter region has been reported (33) . Furthermore, the CpG island 2.5 kb upstream of 5′ UTR of DUSP4/MKP-2 is bound by polycomb group proteins in human ES-cells (34), a feature shared by many tumor suppressor genes methylated in cancer (35) .
Interestingly, methylation was significantly more frequent in sGBM as compared with pGBM. The prevalent methylation of DUSP4/MKP-2 in sGBM and the rare alterations found in pGBM are intriguing because they represent two clinically distinct glioblastoma entities. In this study, we describe for the first time methylation of DUSP4/MKP-2 in human brain tumors. Other members of dual-specificity phosphatases have been reported to be epigenetically regulated in several cancer entities, such as DUSP6/MKP-3, which was found to be hypermethylated in primary pancreatic cancer and pancreatic cell lines (36) .
Ectopic expression of DUSP4/MKP-2 in human diploid fibroblasts leads to premature replicative senescence, whereas inactivation of DUSP4/MKP-2 prohibits senescence (37) . This activity is shared with other tumor suppressor genes, for example, p16INK4a (38, 39) and p21/Waf/Sdi1, initially uncovered as a clone involved in the senescence of human diploid fibroblasts (40) . The fact that epigenetic silencing of DUSP4/MKP-2 is present in low-grade astrocytomas and conserved in tumors that progressed to sGBM argues for a role of DUSP4/MKP-2 early in tumor formation, potentially by evading senescence and allowing the cells to survive and accumulate more genetic/epigenetic alterations as they progress to sGBM.
Inactivation of DUSP4/MKP-2 in sGBM and the established amplification target EGFR in pGBM provide further evidence for a major contribution of the MAPK pathway in the molecular pathogenesis of astrocytic gliomas. Recent findings indicate that EGFR mutations in lung adenocarcinomas are strongly associated with low expression of DUSP4/MKP2 (P < 0.0001) due to broad single-copy losses (41) . The data suggest that DUSP4/MKP2 loss cooperates with EGFR mutation to allow full oncogenic activation of the MAPK pathway. When correlating methylation of DUSP4/MKP-2 with clinical data, we observed a significant association with longer OS in the group of pGBM patients (P = 0.009). A similar association was observed in patients with lung adenocarcinomas, who also showed more favorable outcome when DUSP4/MKP2 was inactivated (41) . Even though we did not perform survival analyses on sGBM due to low sample number, it is interesting to note that we observed a significant correlation between DUSP4/MKP2 methylation and IDH1 mutation because these mutations are associated with an increased OS in secondary glioblastoma patients (4) . In this regard, DUSP4/MKP2 methylation analysis represents a novel potential diagnostic/prognostic marker that will complement IDH1 mutation and the established MGMT promoter methylation analyses.
DUSP4/MKP-2 is located on chromosome 8p12-p11. LOH on 8p was identified in astrocytic gliomas in up to 24% of cases (42, 43) . Interestingly, LOH on 8p12-p11 was exclusively detected in pGBM (13%), whereas none of the six sGBM showed LOH in this region (42) . These studies indicate that structural alterations also occur within the region harboring the DUSP4/MKP-2 gene and that, again, there is a striking distinction between sGBM and pGBM, with only the latter containing deletions of 8p12-p11. In lung adenocarcinomas, single-copy loss on 8p was very frequent, and in breast carcinomas, LOH was observed at markers adjacent to or within DUSP4/MKP-2, supporting its status as a candidate tumor suppressor gene (41, 44, 45) . DUSP4/MKP-2 specifically dephosphorylates and inactivates MAPKs (15) . Because MAPKs strongly influence cell growth and proliferation, inhibition of this cascade by DUSP4/MKP-2 may shut down proliferation and cell survival signaling. We found that overexpression of DUSP4/MKP-2 in glioblastoma cell lines led to a significant reduction of cellular proliferation and focus formation. These data provide further evidence for DUSP4/MKP-2 acting as a growth suppressor. Similar findings showed that ectopic expression of DUSP4/MKP-2 in MCF-7 cells leads to decreased colony formation in soft agar and suppressed tumor formation in nude mice (46) .
In a recent study, a new palindromic site for p53 binding was identified in the promoter region of DUSP4/MKP-2 (25) . These data show that p53 responds to oxidative stress by transcriptional induction of DUSP4/MKP-2 leading to apoptotic cell death. Interestingly, in mouse embryo fibroblasts, DUSP4/MKP-2 can induce apoptosis even in the absence of p53, highlighting the independent role of DUSP4/MKP-2 in signaling apoptosis (25) . In our study, TP53 mutation was significantly more frequent in tumors with DUSP4/MKP-2 methylation, suggesting a role for wild-type p53 in maintaining the active/unmethylated state of DUSP4/MKP-2. Alternatively, signaling by mutant or amplified EGFR may warrant transcriptionally active DUSP4/MKP-2 as part of a negative feed back loop for MAPK desensitization through binding of transcription factors to the DUSP4/MKP-2 promoter and consecutively preventing its methylation. Such a negative feedback loop may explain the high levels of DUSP4/MKP-2 protein observed in several pGBM samples. DUSP4/MKP-2 was identified as a primary target gene of E2F-1 and mediates apoptosis under oxidative stress in MCF-7 cells (46) . In our study, overexpression of DUSP4/ MKP-2 in TP53-mutant glioblastoma cell lines U373MG and A172 did not show an increase in the apoptotic cellular fraction after induction of oxidative stress. This might be due to the cellular context and alterations in genes downstream of DUSP4/MKP-2 responsible for apoptosis. Another explanation for the absence of apoptosis might be redundant activities of other phosphatases, activated following oxidative stress (47) .
In summary, we report on frequent epigenetic downregulation of DUSP4/MKP-2 in AII, AAIII, and sGBM. In pGBM, DUSP4/MKP-2 methylation is rare and associated with longer survival. Furthermore, DUSP4/MKP-2 methylation is more common in TP53-mutant but is absent in EGFR-amplified gliomas. These findings, together with the growth inhibitory effect in vitro, implicate DUSP4/MKP2 as an interesting novel tumor suppressor gene candidate in gliomas.
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